New nanotech-based cancer drug development nearing completion in Moscow

American and Russian scientists in Moscow are jointly gearing up for the launch of a brand new cancer drug based on nanotechnologies

American and Russian scientists in Moscow are jointly gearing up for the launch of a brand new cancer drug based on nanotechnologies, reported Rusnano, Russia?s largest nanotech company. BIND, a U.S.-based biotech developer that received funding from Rusnano last year, is performing clinical trials of the new drug candidate and pushing the project with its Russian partners on the premises of the newly-launched Slava techno-park in the Russian capital. Nanotechnologies at the heart of the new development are believed to enable the delivery of the drug directly into a timorous cell, leaving healthy ones intact?a major difference from indiscriminate impact that the existing therapies have on human tissues. The drug?s active substance is placed in what?s called a special polymer-based matrix. A protective layer, which is part of the technology, helps overcome the resistance of a patient?s immune system and deliver the drug right to the damaged cell...